RecruitingNot ApplicableNCT06516653

Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula

Postmarket Surveillance, Prospective, Multicenter, Randomized, Controlled Study Evaluating the Performance of VasQ for Its Intended Use.


Sponsor

Laminate Medical Technologies

Enrollment

300 participants

Start Date

Jan 13, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

VasQ is an external support implant for arteriovenous fistulas created for dialysis access. This is a postmarket surveillance, prospective, multi-center, randomized, controlled, open label trial enrolling 300 patients randomized into two study arms: * Treatment arm: End to side fistula supported with VasQ * Control: Standard of care end to side fistula


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria4

  • Patients who are candidates for the creation of a new radiocephalic or brachiocephalic end-to-side surgical AV fistula for dialysis access (per VasQ IFU and investigator clinical judgment) and consent to take part in the study.
  • Male and non-pregnant female participants.
  • Age 18-80 years
  • Patients willing and able (physically and geographically) to attend follow up visits over a period of 12 months.

Exclusion Criteria12

  • Index procedure being a revision surgery of an existing fistula.
  • Significantly stenotic target vein on the side of surgery (≥50%) as diagnosed on preoperative ultrasound. (Scan should include the full length of the expected fistula outflow, starting at the planned anastomosis site)
  • Unusual anatomy or vessel dimensions (observed on pre-operative ultrasound or intraoperatively) and which preclude adequate fit of the VasQ.
  • Known central venous stenosis or obstruction on the side of surgery.
  • Pre-existing stents or stent grafts in the access circuit.
  • Planned subsequent fistula superficialization procedure.
  • Known coagulation disorder.
  • Known allergy to nitinol.
  • Expected kidney transplant within 12 months of enrollment.
  • Inability to give consent and/or comply with the study follow up schedule.
  • Insufficient or borderline life expectancy to allow for completion of study procedures and follow-up (12 Months).
  • Participation in another interventional study that in the judgment of the investigator could confound study results.

Interventions

DEVICEVasQ

External support implant for the arteriovenous fistula

PROCEDUREArteriovenous fistula creation for dialysis vascular access

End to side fistula creation in the arm for dialysis vascular access


Locations(7)

Fresenius Vascular Care Long Beach

Long Beach, California, United States

Sarasota Memorial Hospital

Sarasota, Florida, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Greenwood Leflore Hospital

Greenwood, Mississippi, United States

Azura Surgery Center Las Vegas

Las Vegas, Nevada, United States

Fresenius Vascular Care Columbia

Columbia, South Carolina, United States

Fairlawn Surgery Center

Roanoke, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06516653


Related Trials